专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

CA1287584C WOUND-HEALING PREPARATIONS 未知
公开(公告)号：CA1287584C
公开(公告)日：1991-08-13
申请号：CA543536
申请日：1987-07-31
申请人： KOWA CO , TEIKA SEIYAKU KK
发明人： KOMORI SEIICHI , MURAMATSU TOYOJIRO
IPC分类号： A61K33/18
摘要： A wound-healing preparation is composed of 50 90 wt.% of a sugar, 0.5 - 10 wt.% of povidone-iodine, and 1 - 20 wt.% of water. A buffer is also contained in an amount sufficient to adjust the pH of the preparation to 3.5 - 6. Preferably, the preparation may additionally contain 0.1 - 5 wt.% of an agent for imparting an appropriate consistency and stability, which is selected from polysaccharides and derivatives thereof.

2. 发明专利

DE3774374D1 未知
公开(公告)号：DE3774374D1
公开(公告)日：1991-12-12
申请号：DE3774374
申请日：1987-08-21
申请人： KOWA CO , TEIKA SEIYAKU KK
发明人： KOMORI SEIICHI , MURAMATSU TOYOJIRO
IPC分类号： A61K33/18
摘要： A wound-healing preparation is composed of 50 - 90 wt.% of a sugar, 0.5 - 10 wt.% of povidone-iodine, and 1 - 20 wt.% of water. A buffer is also contained in an amount sufficient to adjust the pH of the preparation to 3.5 - 6. Preferably, the preparation may additionally contain 0.1 - 5 wt.% of an agent for imparting an appropriate consistency and stability, which is selected from polysaccharides and derivatives thereof.

3. 发明专利

JP2015091785A トール様受容体４活性化作用を有するフニクロシン誘導体及びその用途审中-公开
公开(公告)号：JP2015091785A
公开(公告)日：2015-05-14
申请号：JP2014201593
申请日：2014-09-30
申请人： UNIV OSAKA , UNIV TOYAMA , TEIKA SEIYAKU KK
发明人： FUJIMOTO YUKARI , FUKASE KOICHI , TAKATSU KIYOSHI , NAGAI YOSHINORI , OKAMOTO NAOKI
IPC分类号： C07D213/69 , A61K31/4418 , A61K31/4433 , A61K31/675 , A61K39/39 , A61P31/00 , A61P37/04 , A61P43/00 , C07D493/04 , C07F9/58 , C07F9/6558
摘要：【課題】TLR4活性化作用又は免疫調節作用を有し、感染防御、抗原の免疫原性の増強等に有用な化合物、医薬等を提供する【解決手段】下記一般式(1)で表される化合物、又はその医薬上許容される塩。【選択図】なし

4. 发明专利

JP2013189450A Eye drop preparation containing latanoprost 审中-公开
标题翻译：含有LATANOPROST的眼药水制剂
公开(公告)号：JP2013189450A
公开(公告)日：2013-09-26
申请号：JP2013104771
申请日：2013-05-17
申请人： Teika Seiyaku Kk , テイカ製薬株式会社
发明人： KIMURA TAKAHITO , WATANABE SHIZUAKI , KOBAYASHI MINORU , SEKI MAKOTO , SHIMATANI TAKAO , TAKAGI CHIHARU
IPC分类号： A61K31/5575 , A61K9/08 , A61K47/02 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/26 , A61K47/38 , A61K47/44 , A61P27/02
CPC分类号： A61K31/215 , A61K9/0048 , A61K31/5575 , A61K47/02 , A61K47/12 , A61K47/18 , A61K47/26
摘要： PROBLEM TO BE SOLVED: To provide an eye drop preparation in which degradation of latanoprost in water is prevented, adsorption of latanoprost onto a plastic container is prevented, and therefore decrease in a latanoprost content is suppressed satisfactorily.SOLUTION: An eye drop preparation is composed of components (A) to (C): (A) latanoprost; (B) a nonionic surfactant; and (C) an organic acid having two or more carboxy groups or a pharmaceutically acceptable salt thereof. Optionally, the eye drop composition is composed of, in place of (C), following components (D) and (E): (D) an organic amine and/or sugars or a derivative thereof; and (E) boric acids and/or phosphoric acids.
摘要翻译：要解决的问题：提供防止水中拉坦前列素降解的滴眼剂制剂，可以防止拉坦前列素吸附在塑料容器上，因此抑制了拉坦前列素含量的降低。解决方案：组合滴眼液制剂的组分（A）至（C）：（A）拉坦前列素; （B）非离子表面活性剂; 和（C）具有两个以上羧基的有机酸或其药学上可接受的盐。任选地，滴眼剂组合物代替（C）由以下组分（D）和（E）组成：（D）有机胺和/或糖或其衍生物; 和（E）硼酸和/或磷酸。

5. 发明专利

JP2008230624A Fluid squeezing container 有权
标题翻译：流体收集容器
公开(公告)号：JP2008230624A
公开(公告)日：2008-10-02
申请号：JP2007068817
申请日：2007-03-16
申请人： Teika Seiyaku Kk , テイカ製薬株式会社
发明人： OBA YASUYO
IPC分类号： B65D47/08 , B65D47/18 , B65D47/20
摘要： PROBLEM TO BE SOLVED: To provide a fluid squeezing container of a simple configuration that makes it possible to take out fluid by a series of simple actions without dropping a cap. SOLUTION: The fluid squeezing container includes a hollow storage body having an injection opening, and a cap fitted over the injection opening. The cap is integrally formed from a cap body having a squeezing opening, a lid covering the upper end of the cap body, thereby sealing the squeezing opening, and a hinge connecting the lid and cap body so that they are freely opened or closed. The storage body has a flexible part that deforms so that its capacity decreases when the lid is squeezed beyond a limit angle in an opening direction and recovers its original shape when the lid returns within a limit angle in the opening direction. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：要解决的问题：提供一种简单构造的流体挤压容器，其使得可以通过一系列简单的动作取出流体而不会掉落帽。解决方案：流体挤压容器包括具有注射开口的中空储存体和装配在注射开口上的帽。盖体由具有挤压开口的盖体，覆盖盖主体上端的盖体一体地形成，从而密封挤压开口，以及连接盖体和盖体的铰链，使得它们自由地打开或关闭。存储体具有柔性部，该变形部在盖在打开方向上被挤压超过极限角度时能够减小，并且当盖返回到打开方向的限制角度时，其恢复其原始形状。版权所有（C）2009，JPO＆INPIT

6. 发明专利

JP2006306757A Remedy for corneal disease 有权
标题翻译：治疗脊髓损害
公开(公告)号：JP2006306757A
公开(公告)日：2006-11-09
申请号：JP2005129450
申请日：2005-04-27
申请人： Teika Seiyaku Kk , テイカ製薬株式会社
发明人： KIMURA TAKAHITO , FUJISHITA SHIGETO , KAWADA HIROYOSHI
IPC分类号： A61K31/53 , A61K9/08 , A61P27/02 , C07D251/18
CPC分类号： A61K9/0048 , A61K31/53 , C07D251/18
摘要： PROBLEM TO BE SOLVED: To discover a medicine capable of effectively treating and improving corneal disease which increases in recent years, and to provide a remedy for the corneal disease containing the medicine as an active ingredient.
SOLUTION: This remedy for the corneal disease contains irsogladine or a salt thereof as the active ingredient. A dosage form of the remedy for the corneal disease comprises an eye lotion.
COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：要解决的问题：发现能够有效治疗和改善近年来增加的角膜疾病的药物，并且为含有该药物作为活性成分的角膜疾病提供补救。解决方案：角膜疾病的这种治疗方法含有作为活性成分的irsogladine或其盐。用于角膜疾病的补救剂的剂型包括眼液。版权所有（C）2007，JPO＆INPIT

7. 发明专利

JP2006298907A Eye drop 审中-公开
标题翻译：眼药水
公开(公告)号：JP2006298907A
公开(公告)日：2006-11-02
申请号：JP2006076083
申请日：2006-03-20
申请人： Kowa Co , Teika Seiyaku Kk , テイカ製薬株式会社 , 興和株式会社
发明人： KIMURA TAKAHITO , AOKI TAKAHIKO , KOBAYASHI MINORU , INAGI TOSHIO , KANEBAKO MAKOTO
IPC分类号： A61K31/734 , A61K31/353 , A61K33/00 , A61K33/26 , A61K45/00 , A61P27/02 , A61P27/06 , A61P43/00
摘要： PROBLEM TO BE SOLVED: To obtain an eye drop that further enhances intraocular pressure lowering effect than a single use of a nitric oxide donative compound and treats glaucoma, ocular hypertension, etc., without using a multiple drug.
SOLUTION: The eye drop comprises a nitric oxide donative compound and alginic acid or its salt. The method for enhancing the efficacy of a nitric oxide donative compound comprises adding alginic acid or its salt to the eye drop comprising a nitric oxide donative compound as an active ingredient. The efficacy enhancer of a nitric oxide donative compound comprises alginic acid or its salt as an active ingredient.
COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：要解决的问题：为了获得与单次使用一氧化氮供体化合物相比进一步提高眼内压降效果的眼药水，并且不使用多种药物治疗青光眼，高眼压症等。解决方案：滴眼剂包含一氧化氮供体化合物和藻酸或其盐。提高一氧化氮供体化合物功效的方法包括向包含一氧化氮供体化合物的滴眼剂中加入海藻酸或其盐作为活性成分。一氧化氮供体化合物的功效增强剂包含海藻酸或其盐作为活性成分。版权所有（C）2007，JPO＆INPIT

8. 发明专利

JP2001064198A THERAPEUTIC AGENT FOR CORNEAL DISEASE 失效
公开(公告)号：JP2001064198A
公开(公告)日：2001-03-13
申请号：JP23682899
申请日：1999-08-24
申请人： TEIKA SEIYAKU KK , BML INC
发明人： KIMURA TAKAHITO , KOIKE JUNPEI , MASUDA KANAKO , KO TAKEKUNI , AIZU YOSHIAKI , KATAYAMA HIROYUKI
IPC分类号： A61K9/08 , A61K38/00 , A61K38/22 , A61P27/02
摘要： PROBLEM TO BE SOLVED: To obtain a therapeutic agent capable of being used for the therapy of corneal damage such as the damage or the like of corneal epidermis, exemplified by corneal ulcer, and useful as an eye drop by making the agent include a ciliary nerve trophic factor as an active ingredient. SOLUTION: This therapeutic agent contains a ciliary nerve trophic factor(CNTF) as an active ingredient. The CNTF can be produced by extracting human glia cell, and mass-produced according to a general gene recombinant technique. A buffer solution of boric acid or the like is used besides a sterilized purified water as the aqueous solvent used for the therapeutic agent, and an enhancer such as sodium chloride, a chelate agent such as sodium edetate, etc., are added thereto. The concentration of the CNTF in the objective therapeutic agent is preferably about 50 ng/ml to 2 mg/ml. The dose is preferably one to six drops (50 μl/drop) per dose, and one to five doses are preferably administered per day.

9. 发明专利

JPH11171779A SEMI-SOLID PREPARATION FOR REPAIRING DAMAGED SKIN 失效
公开(公告)号：JPH11171779A
公开(公告)日：1999-06-29
申请号：JP33539297
申请日：1997-12-05
申请人： KOWA CO , TEIKA SEIYAKU KK
发明人： INAGI TOSHIO , MORI KAZUE , TAKEUCHI HIDETATSU
IPC分类号： A61K9/00 , A61K9/14 , A61K31/70 , A61K33/18 , A61P17/00
摘要： PROBLEM TO BE SOLVED: To obtain the subject preparation that stably retains good sense of use with reduced change in its hardness with time by formulating a plurality of powdery saccharides different in their average particle sizes. SOLUTION: The objective pharmaceutical preparation is obtained by formulating powdery saccharides (as refined sugar, glucose, mannitol and the like) having different average particle sizes in the range of preferably from 10-1,200 μm (the powdery saccharides of 10-100 μm and of 150-800 μm are mixed at a weight ratio of 1/1-99/1), preferably in an amount of 50-90 wt.%. In a preferred embodiment, 0.5-10 wt.% of an antimicrobial agent as providone iodine, 10-40 wt.% of a shape-retaining agent as dextrin, 0.5-30 wt.% of a solubilizer as potassium iodide and 1-30 wt.% of water are additionally formulated and the pH of the preparation is adjusted to 3.5-6.0 with a pH controller as hydrochloric acid, sodium hydroxide or the like.

10. 发明专利

JPH1087494A PIROXICAM-FORMULATED PATCM FOR EXTERNAL USE 失效
公开(公告)号：JPH1087494A
公开(公告)日：1998-04-07
申请号：JP26548996
申请日：1996-09-15
申请人： TEIKA SEIYAKU KK
发明人： ISHIGURO YUKIO , YONEZAWA SHINOBU , YOSHIDA KAORI
IPC分类号： A61K9/70 , A61K31/54 , A61K47/32 , A61P25/04 , A61P29/00
摘要： PROBLEM TO BE SOLVED: To obtain the subject path improved in the percutaneous absorbability of piroxicam, having potent antiinflammatory effect and retaining good stability of the active ingredient. SOLUTION: This patch for external use contains (a) 0.1-10wt.% of piroxicam and (b) a polyethylene glycol stearic ester (and polyoxyethylene sorbitan stearic ester).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式